預測性生物標記市場：策略性洞察與預測（2026-2035 年）

預測性生物標記市場預計將從 2026 年的 289 億美元成長到 2035 年的 743 億美元，複合年成長率為 11.1%。

預測性生物標記市場正經歷模式轉移。這一市場演變的特點是，人們日益認知到可測量的生物學特徵對於識別最有可能對特定治療性介入反應的患者至關重要，這使得預測性生物標記成為多個治療領域精準醫療策略不可或缺的一部分。次世代定序、數位病理學和人工智慧 (AI) 等先進分子技術的融合，正在推動更全面、更標準化的生物標記發現和檢驗。隨著患者選擇準確性的提高，臨床試驗效率和法規核准率也隨之提升，製藥公司正將生物標記策略整合到臨床開發中。生物標記療法在自體免疫疾病、循環系統疾病、神經退化性疾病和感染疾病等領域也展現出臨床效用，其需求正從腫瘤學領域擴展到其他領域。隨著對液態生物檢體技術、多體學平台和人工智慧分析工具的大量投資，預測性生物標記正逐漸成為全球醫療機構現代醫療保健的戰略支柱。

市場促進因素

• 精準腫瘤學的擴展是預測性生物標記市場的主要驅動力。精準腫瘤學依賴預測性生物標記物，將個別腫瘤中存在的分子突變與標靶治療相匹配。隨著標靶抗癌藥物組合的不斷擴大，在開始治療前檢驗的生物標記檢測的需求也在穩步成長。分子異質性限制了經驗性治療方案的選擇，並增加了治療失敗的風險。因此，製藥公司正在將預測性生物標記納入其臨床開發項目，以改善患者分層並驗證治療效果。這種整合提高了伴隨診斷的商業性價值，同時也擴大了腫瘤學實踐整體常規分子檢測的範圍，並推動了預測性生物標記應用的持續成長。次世代定序(NGS) 透過實現全面的生物標記檢測，進一步加速了市場成長。 NGS 允許在單次檢測中同時分析多個具有臨床意義的基因突變。全面的基因組分析減少了對連續檢測的需求，並節省了有限的組織樣本，促使臨床檢查室擴大採用多重檢測。複雜的分子資料集帶來了解讀上的挑戰，需要先進的生物資訊技術和標準化的報告方法。診斷公司正透過整合臨床決策支援軟體和定序平台來應對這項挑戰，從而增強醫師的信心。製藥公司正在藥物研發的早期階段引入生物標記物，以提高臨床試驗的效率。在藥物研發中，預測性生物標記擴大從臨床開發的早期階段就被納入，以便在大型試驗開始前識別可能對治療產生反應的患者群體。由於患者入組的異質性通常會降低統計效力，因此臨床開發項目需要可靠的分子水平分層。臨床試驗贊助者在加強與診斷開發商的合作，以便在III期臨床試驗開始前建立檢驗的生物標記檢測方法。這種合作開發模式支持治療藥物和伴隨診斷試劑的同步監管審查，並提高商業化準備。人工智慧（AI）透過先進的計算分析提高了生物標記發現的效率。 AI透過分析大規模基因組、蛋白質組、影像和臨床資料集來加速生物標記的識別。隨著生物複雜性超越傳統分析能力，研究機構對計算方法的需求日益成長。

市場限制因素

• 臨床檢驗需要龐大且多樣化的患者群體，這增加了研發成本並延長了商業化時間。嚴格的證據要求給研發人員帶來了巨大的時間和成本負擔。檢查室間標準化程度不足降低了預測性生物標記結果的可重複性，影響了臨床可靠性。缺乏統一的方案對臨床決策的一致性構成挑戰。不同醫療體系的報銷政策仍有差異，限制了除高優先治療領域之外的常規應用。保險覆蓋範圍的區域差異給診斷服務提供者帶來了不確定性，並限制了患者的就醫途徑。不同司法管轄區的監管複雜性給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

目錄

第1章：執行摘要

• 市場概述
• 主要發現
• 分析師意見
• 策略建議

第2章：調查方法

• 調查設計
• 資料收集和調查方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 全球生物標記市場預測：概述、市場規模和預測

• 市場定義和範圍
• 行業概覽
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測分析
• 疾病負擔與預測性生物標記的臨床意義
• 精準醫學中的預測性生物標記
• 生物標記發現和臨床檢驗的現狀
• 伴隨診斷的現狀
• 對所進行的生物標記檢測數量進行分析
• 按主要疾病領域進行的患者族群分析

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新型生物標記技術
• 產品創新的整體概況
• 預測性生物標記臨床試驗的分析
• 伴隨診斷開發平臺分析
• 多體學和整合生物標記開發
• 人工智慧在預測性生物標記發現的應用
• 數位病理學與計算生物學生物標記的整合

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：全球生物標記市場預測：展望分析

• 分析：依生物標記類型
• 分析：按技術平台
• 分析：檢體類型
• 分析：透過臨床應用
• 分析：按疾病指徵
• 分析：透過測試方法
• 分析：按最終用戶

第9章 全球生物標記市場預測：細分市場分析

• 依生物標誌類型
  • 基因生物標記
  • 蛋白質體學生物標記
  • 表觀遺傳生物標記
  • 其他
• 透過技術
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學（IHC）
  • 原位雜合反應（ISH）
  • 其他分子技術
• 依檢體類型
  • 組織
  • 血
  • 尿
  • 唾液
  • 其他生物體液
• 按疾病指徵
  • 瘤
  • 自體免疫疾病
  • 心血管疾病
  • 神經病變
  • 感染疾病
  • 其他慢性疾病
• 透過臨床應用
  • 伴隨診斷
  • 藥物發現與開發
  • 疾病風險預測
  • 毒性預測
  • 其他
• 最終用戶
  • 醫院
  • 臨床實驗室
  • 製藥和生物技術公司
  • 其他

第10章：全球生物標記市場預測：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章 全球生物標記市場預測：國家分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 日本
• 中國
• 印度
• 韓國
• 澳洲
• 巴西
• 沙烏地阿拉伯
• 南非

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd.
• QIAGEN NV
• Agilent Technologies, Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• NeoGenomics Laboratories
• Guardant Health, Inc.
• Exact Sciences Corporation

第14章 全球生物標記市場預測：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Predictive Biomarkers Market is expected to grow at a CAGR of 11.1% from a market value of USD 28.9 billion in 2026 to USD 74.3 billion in 2035.

The predictive biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine and biomarker-guided therapeutic selection. The market's evolution is characterized by the growing recognition that measurable biological characteristics are essential for identifying patients likely to respond to specific therapeutic interventions, making predictive biomarkers integral to precision medicine strategies across multiple therapeutic areas. The convergence of advanced molecular technologies, including next-generation sequencing, digital pathology, and artificial intelligence, is enabling more comprehensive and standardized biomarker discovery and validation. Pharmaceutical companies are integrating biomarker strategies into clinical development because enriched patient selection improves trial efficiency and increases regulatory success. Demand is increasingly moving beyond oncology as biomarker-guided approaches demonstrate clinical utility in autoimmune diseases, cardiovascular medicine, neurodegenerative disorders, and infectious diseases. The market is witnessing significant investment in liquid biopsy technologies, multi-omics platforms, and AI-enabled interpretation tools, positioning predictive biomarkers as a strategic pillar of modern healthcare across global medical practice.

Market Drivers

• The expansion of precision oncology represents the primary driver for the predictive biomarkers market. Precision oncology relies on predictive biomarkers to match targeted therapies with molecular alterations present within individual tumors. Demand is steadily increasing because expanding portfolios of targeted oncology drugs require validated biomarker testing before treatment initiation. Molecular heterogeneity limits empirical treatment selection and increases the risk of therapeutic failure. Pharmaceutical sponsors are therefore incorporating predictive biomarkers into clinical development programs to improve patient stratification and demonstrate treatment efficacy. This integration strengthens the commercial value of companion diagnostics while expanding routine molecular testing across oncology practice, resulting in sustained growth in predictive biomarker utilization. Next-generation sequencing is further accelerating market growth by enabling comprehensive biomarker testing. NGS enables simultaneous analysis of numerous clinically relevant genetic alterations within a single assay. Clinical laboratories are increasingly adopting multiplex testing because comprehensive genomic profiling reduces sequential testing requirements and preserves limited tissue samples. Complex molecular datasets create interpretation challenges that require advanced bioinformatics and standardized reporting. Diagnostic companies are responding by integrating sequencing platforms with clinical decision-support software that improves physician confidence. Pharmaceutical companies are embedding biomarkers earlier in drug development to improve trial efficiency. Drug development increasingly incorporates predictive biomarkers during early clinical phases to identify responsive patient populations before pivotal studies begin. Clinical development programs require reliable molecular stratification because heterogeneous patient enrollment often reduces statistical power. Sponsors are increasingly collaborating with diagnostic developers to establish validated biomarker assays before Phase III investigations commence. This coordinated development approach supports simultaneous regulatory review of therapeutics and companion diagnostics while improving commercial launch readiness. Artificial intelligence is improving biomarker discovery efficiency through advanced computational analysis. AI accelerates biomarker identification by analyzing large-scale genomic, proteomic, imaging, and clinical datasets. Research organizations increasingly require computational approaches because biological complexity exceeds traditional analytical capabilities.

Market Restraints

• Clinical validation requires large, diverse patient populations, increasing development cost and extending commercialization timelines. The rigorous evidence requirements create significant time and cost burdens for developers. Limited standardization across laboratories reduces reproducibility of predictive biomarker results and affects clinical confidence. The lack of harmonized protocols creates challenges for consistent clinical decision-making. Reimbursement policies remain inconsistent across healthcare systems, restricting routine adoption outside high-priority therapeutic areas. Coverage differences across regions create uncertainty for diagnostic providers and limit patient access. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

• The technology landscape is characterized by the growing importance of integrated multi-omics platforms and AI-enabled interpretation. Genomic biomarkers represent the largest segment because they directly identify genetic alterations associated with therapeutic responsiveness. Demand is increasing as targeted therapies require precise identification of actionable mutations before treatment initiation. Diagnostic manufacturers are expanding multiplex sequencing platforms that evaluate numerous clinically relevant genes within a single assay. NGS is expanding comprehensive biomarker testing capabilities and improving diagnostic efficiency. PCR remains important for focused mutation detection where rapid turnaround is prioritized. IHC and ISH continue supporting protein and gene expression biomarker assessment. Liquid biopsy is expanding predictive biomarker accessibility through minimally invasive assessment of circulating tumor DNA and other molecular biomarkers from blood samples. The segment analysis reveals that oncology dominates predictive biomarker utilization because cancer treatment increasingly depends on molecular stratification rather than tumor location alone. Expanding targeted therapy portfolios are increasing demand for companion diagnostics that identify eligible patients with high analytical accuracy. Companion diagnostics constitute the leading clinical application because numerous targeted therapies require validated biomarker testing before prescription. Regulatory agencies emphasize synchronized therapeutic and diagnostic approval to ensure appropriate patient selection. Autoimmune disorders represent a rapidly evolving application area because biologic therapies demonstrate variable effectiveness across patient populations. Cardiovascular medicine is incorporating predictive biomarkers to improve risk stratification and therapeutic optimization. Clinical laboratories represent the leading end-user segment, with hospitals and pharmaceutical companies expanding biomarker utilization. The integration of AI is becoming increasingly important because AI accelerates biomarker identification by analyzing large-scale genomic, proteomic, imaging, and clinical datasets.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized precision medicine and AI-driven analytics providers. Roche maintains one of the industry's largest companion diagnostic portfolios integrated with targeted therapeutics, with its combined pharmaceutical and diagnostics businesses creating strong alignment between biomarker discovery and precision medicine commercialization. QIAGEN specializes in molecular diagnostics, sample technologies, and companion diagnostic partnerships with global pharmaceutical companies, with its broad assay portfolio supporting biomarker identification from research through clinical practice. Agilent delivers genomics, pathology, and biomarker analysis platforms supporting translational research and clinical diagnostics, continuing to expand precision medicine capabilities through advanced molecular testing solutions. Illumina is a global leader in NGS technologies used for comprehensive genomic profiling and biomarker discovery, with its sequencing platforms underpinning precision medicine research and companion diagnostic development worldwide. Thermo Fisher offers integrated genomic analysis, PCR, sequencing, and clinical diagnostic platforms supporting predictive biomarker development, enabling end-to-end precision medicine workflows. Abbott develops molecular diagnostic systems and precision testing solutions supporting infectious disease and oncology applications. Bio-Rad provides digital PCR, quality control, and molecular diagnostic technologies supporting highly sensitive biomarker detection. NeoGenomics specializes in oncology-focused clinical laboratory services, including molecular testing and comprehensive genomic profiling. Guardant Health focuses on liquid biopsy technologies using circulating tumor DNA for precision oncology applications. Companies are pursuing product portfolio expansion through innovation in multi-omics platforms, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include Nucs AI partnering with Segmed to build the validation foundation for the next generation of AI in oncology, with Segmed becoming Nucs AI's preferred data partner for oncology alongside a strategic investment. Bio-Techne partnered with Nucleai to launch an AI-powered spatial biology workflow designed to accelerate predictive biomarker discovery in melanoma research. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The predictive biomarkers market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and expanding healthcare investment. The transition from supportive laboratory tools toward fundamental components of therapeutic development and clinical decision-making represents a fundamental shift in healthcare delivery. While challenges related to clinical validation, standardization, and reimbursement variability persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with predictive biomarkers evolving into a strategic pillar of modern healthcare, supporting personalized treatment selection, improved clinical outcomes, and optimized healthcare resource utilization across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Predictive Biomarkers Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden & Clinical Significance of Predictive Biomarkers
• 3.8 Predictive Biomarkers in Precision Medicine
• 3.9 Biomarker Discovery and Clinical Validation Landscape
• 3.10 Companion Diagnostics Landscape
• 3.11 Biomarker Testing Volume Analysis
• 3.12 Patient Population Analysis by Major Disease Area

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Technologies
• 6.2 Product Innovation Landscape
• 6.3 Clinical Trial Analysis for Predictive Biomarkers
• 6.4 Companion Diagnostic Development Pipeline Analysis
• 6.5 Multi-Omics and Integrated Biomarker Development
• 6.6 Artificial Intelligence in Predictive Biomarker Discovery
• 6.7 Digital Pathology and Computational Biomarker Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Predictive Biomarkers Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Technology Platform
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Disease Indication
• 8.6 Analysis by Testing Methodology
• 8.7 Analysis by End User

9. Global Predictive Biomarkers Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Genomic Biomarkers
  • 9.1.2 Proteomic Biomarkers
  • 9.1.3 Epigenetic Biomarkers
  • 9.1.4 Others
• 9.2 By Technology
  • 9.2.1 Next-Generation Sequencing (NGS)
  • 9.2.2 Polymerase Chain Reaction (PCR)
  • 9.2.3 Immunohistochemistry (IHC)
  • 9.2.4 In Situ Hybridization (ISH)
  • 9.2.5 Other Molecular Technologies
• 9.3 By Sample Type
  • 9.3.1 Tissue
  • 9.3.2 Blood
  • 9.3.3 Urine
  • 9.3.4 Saliva
  • 9.3.5 Other Biofluids
• 9.4 By Disease Indication
  • 9.4.1 Oncology
  • 9.4.2 Autoimmune Disorders
  • 9.4.3 Cardiovascular Diseases
  • 9.4.4 Neurological Disorders
  • 9.4.5 Infectious Diseases
  • 9.4.6 Other Chronic Diseases
• 9.5 By Clinical Application
  • 9.5.1 Companion Diagnostics
  • 9.5.2 Drug Discovery & Development
  • 9.5.3 Disease Risk Prediction
  • 9.5.4 Toxicity Prediction
  • 9.5.5 Others
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Clinical Laboratories
  • 9.6.3 Pharmaceutical & Biotechnology Companies
  • 9.6.4 Others

10. Global Predictive Biomarkers Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Predictive Biomarkers Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 QIAGEN N.V.
• 13.3 Agilent Technologies, Inc.
• 13.4 Illumina, Inc.
• 13.5 Thermo Fisher Scientific Inc.
• 13.6 Abbott Laboratories
• 13.7 Bio-Rad Laboratories, Inc.
• 13.8 NeoGenomics Laboratories
• 13.9 Guardant Health, Inc.
• 13.10 Exact Sciences Corporation

14. Global Predictive Biomarkers Market Commercial Forecast Analysis

• 14.1 Companion Diagnostic Assays
• 14.2 Next-Generation Sequencing-Based Biomarker Panels
• 14.3 PCR-Based Predictive Biomarker Tests
• 14.4 Immunohistochemistry-Based Biomarker Assays
• 14.5 Liquid Biopsy-Based Predictive Biomarker Tests
• 14.6 Multiplex Molecular Biomarker Panels
• 14.7 AI-Enabled Biomarker Interpretation Solutions

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends